Altamira Therapeutics Ltd. announced that it has entered into a collaboration agreement with Univercells Group (Univercells) to evaluate the use of the company's proprietary SemaPhore platform for the delivery of mRNA vaccines. Univercells is a global life sciences company creating platforms for developing and manufacturing biologics, including mRNA vaccines and therapeutics, in a simple, scalable and cost-efficient way. Under the terms of the agreement, Univercells will test in vitro and in vivo a proprietary mRNA vaccine delivered with Altamira's SemaPhore nanoparticle platform.

Should the experiments prove successful, Univercells and Altamira intend to discuss and negotiate a commercial agreement for the development and manufacturing of nanoparticle-based mRNA vaccines using Univercells' production platform. mRNA vaccines work through priming the body?s immune system to recognize and destroy a pathogen. The vaccines introduce a small piece of the target pathogen?s proteins into specialized cells in its bodies that can produce the full protein.

These cells then manufacture the target protein in small amounts triggering the production of specific antibodies to destroy any entity that has the same protein, such as a virus.